检索结果 - Alei Feng

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features

    Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features 由 Qiang Wen, Zhe Yang, Honghai Dai, Alei Feng, Qiang Li

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer

    Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Pati... 由 Qingtao Qiu, Ligang Xing, Yu Wang, Alei Feng, Qiang Wen

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    <p>Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC</p>

    <p>Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC</p> 由 Qiang Wen, Zhe Yang, Jian Zhu, Qingtao Qiu, Honghai Dai, Alei Feng, Ligang Xing

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study

    The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study 由 Jisheng Li, Cong Lei, Jintao Liu, Ling Peng, Jun Wang, Alei Feng, Jinbo Yue, Li Li, Xiuwen Wang, Xiangling Wang

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy

    Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy 由 Dapeng Yu, Shuisheng Zhang, Alei Feng, Deguo Xu, Qingshan Zhu, Yantao Mao, Yi Zhao, Yajuan Lv, Cuiping Han, Rujun Liu, Yuan Tian

    出版 2019
    获取全文
    Revisão
    加到收藏夹
    Saved in:

检索工具: